Dear Reader, On behalf of the SINDOFO Consortium, we wish you a happy, healthy and successful 2023. 2022 was an eventful year for the project with a lot of achievements
Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study
The Lancet infectious diseases
Peer reviewed article